em J Pediatr Gastroenterol Nutr /em 2017; 65:346C349. Table ?Table11. TABLE 1 Macronutrient and mineral profile of study products per 100 kcal of prepared product M16-V, CFU2.11??109CMinerals?Sodium, mg4037?Potassium, mg105155?Chloride, mg7577?Calcium, mg90124?Phosphorus, mg6393?Magnesium, mg11.212.4?Iron, mg1.51.9?Zinc, mg1.11.7?Copper, g76124?Manganese, g7690?Selenium, g2.83.7?Iodine, g17.515.4Mineral sourcesCalcium phosphate dibasic, tripotassium citrate, sodium chloride, magnesium chloride, tricalcium citrate, magnesium l-aspartate, ferrous slphate, zinc sulphate, calcium d-pantothenate, manganese sulphate, cupric sulphate, potassium iodide, chromium chloride, sodium selenite, sodium molybdate Open in a separate window *Differences in blood chemistry parameters (at baseline, week 16, and change from baseline) between Vps34-IN-2 the study products have been analysed before and were not found to be statistically significant or clinically relevant (1,3) and are therefore presented for the combined (Neocate with or without synbiotics) group. Serum concentrations of phosphorus, calcium, and magnesium were decided at baseline (n?=?82) and after 16 weeks (n?=?66) on AAF and compared to age-specific reference ranges. Subgroup analysis was performed for infants who were receiving acid-suppressive drugs (proton-pump-inhibitors/H2-antagonists), that is, approximately one-third (35%) of our sample. Between-group comparisons were made by 2-tailed Student tests. values 0.05 were considered as not significant. Serum concentrations of phosphorus, calcium, and magnesium for the total population and for the subgroups of infants receiving or not receiving acid-suppressive drugs are Vps34-IN-2 offered in Tables ?Furniture22 and ?and3.3. After 16 weeks, mineral concentrations of all infants were within the reference range. TABLE 2 Serum concentrations (imply, 95% confidence Vps34-IN-2 interval) of phosphorus (P), calcium (Ca), and magnesium (Mg) and number (n, %) of infants having P, Ca, and Mg concentration below the lowest range of the reference value at baseline value: users vs nonusersvalue: users vs nonusers /thead em P /em , mmol/L1.961.91C2.0101.951.88C2.0301.971.90C2.040nsCa, mmol/L2.622.59C2.6502.632.59C2.6802.612.58C2.650nsMg, mmol/L0.950.94C0.9700.960.94C0.9900.950.92C0.970ns Open in a separate window Reference ranges em P /em : 1.36C2.62 ( 1 years) and 1.03C1.97 (1 years) mmol/L; Ca: 2.25C2.74?mmol/L; Mg: 0.70C0.98 ( 30 days), 0.66C1.03 (males, 30 days), and 0.78C0.98 (females, 30 Vps34-IN-2 days) mmol/L. ns = not significant. Our data show that, although doses, compliance, and the neutralizing effect of the acid-suppressive drugs were not measured and infants were not randomized for acid-suppressive drug use, cow’s milk allergic infants orally fed with AAF for 16 weeks maintain target serum concentrations of phosphorus, calcium, and magnesium even when receiving acid-suppressive drugs. Regular review of the ongoing need for acid-suppressive drugs remains recommended. Recommendations 1. Harvey BM, Eussen S, Harthoorn LF, et al. Mineral intake and status of cow’s milk allergic ZKSCAN5 infants consuming an amino acid-based formula. em J Pediatr Gastroenterol Nutr /em 2017; 65:346C349. [PMC free article] [PubMed] [Google Scholar] 2. Champagne ET. Low gastric hydrochloric acid secretion and mineral bioavailability. em Adv Exp Med Biol /em 1989; 249:173C184. [PubMed] [Google Vps34-IN-2 Scholar] 3. Burks AW, Harthoorn LF, Van Ampting MT, et al. Synbiotics-supplemented amino acid-based formula supports adequate growth in cow’s milk allergic infants. em Pediatr Allergy Immunol /em 2015; 26:316C322. [PubMed] [Google Scholar].